McKesson Corporation (MCK) Financial Statements
Historical financial data — 43 statements covering FY2016–FY2026
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, inde...
McKesson Corporation's revenue increased 12.4% year over year, from $359.05B to $403.43B.
Net income increased 44.5% over the same period, from $3.29B to $4.76B.
Over the 10-year period from FY2016 to FY2026, revenue grew by 111% in total.
Total debt increased by 15.8% to $6.56B.
Operating cash flow grew 1.2% to $6.16B.
McKesson Corporation maintains a moderate net profit margin of 1.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2024 | $74.48B-64.2% | $958.0M | $3.02B | $1.10B | $-1.05B | $64.10B | $5.66B | $-1.60B |
| Q2 FY2024 | $151.70B+103.7% | $1.62B | $6.09B | $2.05B | $-87.0M | $66.09B | $5.58B | $-1.83B |
| Q3 FY2024 | $232.60B+53.3% | $2.21B | $9.24B | $2.69B | $167.0M | $66.51B | $5.84B | $-2.05B |
| Q1 FY2025 | $79.28B-65.9% | $915.0M | $3.15B | $1.03B | $-1.38B | $71.67B | $5.63B | $-1.75B |
| Q3 FY2025 | $268.23B+238.3% | $2.04B | $9.68B | $2.83B | $-1.66B | $71.08B | $6.85B | $-3.08B |
| Q1 FY2026 | $97.83B-63.5% | $784.0M | $3.28B | $1.04B | $-918.0M | $81.31B | $7.73B | $-1.97B |
| Q2 FY2026 | $200.98B+105.4% | $1.89B | $6.82B | $2.44B | $1.50B | $84.16B | $7.71B | $-1.74B |
| Q3 FY2026 | $307.13B+52.8% | $3.08B | $10.51B | $4.06B | $2.73B | $84.19B | $6.53B | $-1.30B |
Balance Sheet Summary (Latest Period)
Total Assets
$82.32B
Total Liabilities
$84.50B
Total Equity
$-2.17B
Cash & Equivalents
$3.98B
Total Debt
$6.56B
Current Assets
$57.21B
Current Liabilities
$67.02B
Retained Earnings
$22.29B